Kyverna Completes Miv-cel FDA Application for Stiff Person Syndrome
The company is seeking priority review as it prepares for a potential 2027 launch and reports a third-quarter net loss of $41.9 million.
Makkler Newsroom · Nov 12, 04:52 PM · 1 min read
